anti-interleukin-5 antibody

Anti-interleukin-5 (IL-5) antibodies are a class of biologic therapies, specifically monoclonal antibodies, designed to neutralize the IL-5 cytokine. IL-5 is the primary cytokine responsible for the growth, differentiation, recruitment, and activation of eosinophils, which are key inflammatory cells in several respiratory and systemic diseases. By binding to IL-5, these antibodies prevent it from interacting with the IL-5 receptor complex on the surface of eosinophils, thereby reducing eosinophilic inflammation. This therapeutic class includes approved agents such as mepolizumab (Nucala) and reslizumab (Cinqair). They are primarily indicated for the add-on maintenance treatment of severe eosinophilic asthma, but members of the class have also been approved or studied for conditions such as eosinophilic granulomatosis with polyangiitis (EGPA), chronic rhinosinusitis with nasal polyps, and hypereosinophilic syndrome (HES).

Brand names

NucalaCinqair

Other names

anti-IL-5 antibodyanti-IL5 antibodyanti-IL 5 antibodyIL-5 antibodyIL5 antibodyIL 5 antibody